Laboratory Diagnosis of APS

Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Maggiore Hospital and Humanitas University, Milano Italy

Journal of Thrombosis and Haemostasis, 16: 809-813

DOI: 10.1111/jth.13976

RECOMMENDATIONS AND GUIDELINES

Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH

K. M. J. DEVREESE, * D T. L. ORTEL, † V. PENGO‡ and B. DE LAAT§¶FOR THE SUBCOMMITTEE ON LUPUS ANTICOAGULANT/ANTIPHOSPHOLIPID ANTIBODIES

*Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; †Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC, USA; ‡Cardiology Department, University of Padova, Padova, Italy; §Department of Biochemistry, Maastricht University; and ¶Synapse BV, Maastricht, the Netherlands

Antiphospholipid Syndrome Condition defined by clinical and lab criteria

- Laboratory criteria
- Lupus anticoagulant and/or solid-phase antiphospholipid antibody positive tests (confirmed on 2 occasions 12 weeks apart)
- Clinical criteria
- Pregnancy complications, venous and/or arterial thrombosis

Solid-phase Antiphospholipid Antibodies

- Which Test(s)
- Anti-cardiolipin
- $-Anti-\beta_2 GPI$
- Anti-PS/PT
- Which Isotype(s)
 - IgG
 - IgM

There are many commercial assays available for aCL or a-ß₂GPI

But they are not yet standardized across laboratories

Assays for aCL and $a-\beta_2 GPI$

- Many commercial ELISA-based assays
- Poorly standardized. Gross degree of variation across labs
- Chemiluminescence-based assays
- Closed systems (easy handling of reagents and samples)

Laboratory Detection of LA

Journal of Thrombosis and Haemostasis, 7: 1737–1740

DOI: 10.1111/j.1538-7836.2009.03555.x

OFFICIAL COMMUNICATION OF THE SSC

Update of the guidelines for lupus anticoagulant detection

V. PENGO, * A. TRIPODI, † G. REBER, ‡ J. H. RAND, § T. L. ORTEL, ¶ M. GALLI** and P. G. DE GROOT†† *Clinical Cardiology, Thrombosis Center, University Hospital, Padova; †Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, University and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy; ‡Haemostasis Unit, Division of Angiology and Haemostasis, University Hospital, Geneva, Switzerland; §Hematology and Advanced Coagulation Laboratory, Montefiore Medical Center, Bronx, NY; ¶Division of Hematology, Duke University Medical Center, Durham, NC, USA; **Department of Hematology, Ospedali Riuniti, Bergamo, Italy; and ††Department of Clinical Chemistry and Haematology, University Medical Centre, Utrecht, the Netherlands

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic criteria
- When testing
- Results reporting
- Interpretation

Indications to search for APS

- Occurrence of (accidentally-found) prolongation of the APTT without known etiology
- Patients with venous and/or arterial thrombosis at young age (<50 years)
- Patients with thrombosis at unusual sites, or associated with autoimmune diseases
- Women with pregnancy complications

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic Criteria
- When testing
- Results reporting
- Interpretation

Which Test

- Two tests based on different principles
- dRVVT
- <u>Sensitive aPTT-based test</u> (low phospholipids and silica as activator)

LA should be considered as positive if at least one of the two tests is positive

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic Criteria
- When testing
- Results reporting
- Interpretation

Diagnostic Criteria for LA Detection

Screening

- Prolongation of phospholipid-dependent clotting test
- Mixing
- Evidence that the prolongation is due to the presence of an inhibitor
- Confirmation
- Evidence that the inhibitor is directed against phospholipids

Screening How to determine cut-off values

- Perform testing on plasmas from healthy donors
- Take the cut-off as the value above the 99th percentile of the distribution

Mixing

How to determine cut-off values

- Perform testing on plasmas from healthy donors, mixed with PNP at 1:1 proportion
- Take the cut-off as the value above the 99th percentile of the distribution
- Alternatively, the cut-off may be the value of the ICA defined according to:

$$ICA = [(CT_{mix} - CT_{PNP}/CT_{patient})]x100$$

Confirmation How to determine cut-off values

- Perform testing on plasmas from healthy donors at low (screen) and high (confirm) phospholipid concentrations
- Take the cut-off as the value above the 99th percentile of the distribution of the individual % corrections calculated according to:

% Corr. = [(screen - confirm)/screen] x 100

ORIGINAL ARTICLE

Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study

A. TRIPODI, * V. CHANTARANGKUL, * M. CINI, † K. DEVREESE, ‡ J. S DLOTT, § R. GIACOMELLO, ¶ * * E. GRAY, † † C. LEGNANI, † M. E. MARTINUZZO, ‡ P. PRADELLA, § § A. SIEGEMUND, ¶¶ S. SUBRAMANIAN, * * * P. SUCHON † † † ‡ ‡ ‡ and S. TESTA § §

Essentials

- Cut-off values for LA detection were calculated in 11 labs each testing plasma from 120 donors with 3 commercial platforms
- Major variations were observed even within the same platform
- Cut-off values determined in any given lab are not necessarily interchangeable

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic Criteria
- When testing
- Results reporting
- Interpretation

When Testing

Problem

 Results interpretation is difficult during acute thrombosis and/or during antithrombotic drugs

Recommendation

 Blood should be collected before starting anticoagulation or after a sufficient period from its discontinuation

Effect of Anticoagulation on LA Testing

- Heparin mimics LA
- Many LA tests do contain heparin neutralizers
- LMWH may mimic LA
- Depending on the brand of LMWH used
- Especially at peak
- VKA give rise to false-positive (or negative) LA
- DOAC give rise to false-positive LA

Approaches to Overcome Anticoagulation

- Dilution (1:1) of patient plasma into pooled normal plasma (PNP)
- Integrated assays (screen and confirm)
- Tests (reportedly) less affected by anticoagulants
- Antidotes or neutralizers to quench *in vitro* the activity of anticoagulants
- Discontinuation of anticoagulation

Dilution (1:1) of patient plasma into PNP

Rationale


- Deficiency of coagulation will be corrected by the PNP
- Limitations
- Applicable only to VKA
- Good quality PNP
- Dilution reduces (by 50%) the LA potency
- Correction by PNP is dependent on the APTT or dRVVT used for testing
- No conclusive evidence on the value of the procedure

False-negative or false-positive LA should be expected

Approaches to Overcome Anticoagulation

- Dilution (1:1) of patient plasma into pooled normal plasma (PNP)
- Integrated assays (screen and confirm)
- Tests (reportedly) less affected by anticoagulants
- Antidotes or neutralizers to quench *in vitro* the activity of anticoagulants
- Discontinuation of anticoagulation

Schematic representation of Integrated LA Test



Integrated LA Tests

- Earlier reports suggested that screen and confirm integrated tests in the presence of VKA or UFH are proportionally prolonged
- Hence, they are reliable for the majority of patients even in the presence of UFH or VKA
- Later reports showed that screen and confirm in the presence of DOAC are not proportionally prolonged
- Screen tends to be more prolonged than confirm
- Consequently, the ratio screen/confirm tends to be higher than expected and may lead to false-positive LA

Approaches to Overcome Anticoagulation

- Dilution (1:1) of patient plasma into pooled normal plasma (PNP)
- Integrated assays (screen and confirm)
- Tests (reportedly) less affected by anticoagulants
- Antidotes or neutralizers to quench *in vitro* the activity of anticoagulants
- Discontinuation of anticoagulation

Tests (reportedly) less affected by anticoagulants

- Snake venoms (Taipan & Ecarin) might be useful to detect LA during anticoagulation, as they are able to activate FII
- Taipan is a PL- and calcium-dependent activator, whilst Ecarin is not
- If used in combination they may help detecting LA during anticoagulation
- There is information from literature on their diagnostic efficacy on patients on VKA, but not conclusive evidence

Approaches to Overcome Anticoagulation


- Dilution (1:1) of patient plasma into pooled normal plasma (PNP)
- Integrated assays (screen and confirm)
- Tests (reportedly) less affected by anticoagulants
- Antidotes or neutralizers to quench *in vitro* the activity of anticoagulants
- Discontinuation of anticoagulation

Antidotes/Neutralizers to Quench Anticoagulants

- Idarucizumab added in vitro to neutralize dabigatran
- Andexanet alfa added in vitro to neutralize anti-FXa drugs
- DOAC-Stop[®], or DOAC-Remove[®]
- Activated charcoal added in vitro to adsorb DOAC

Thromb Res 2019; 180:10-19

Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa



Essentials

Rivaroxaban caused clotting time prolongation for most LA tests and generated falsely elevated dRVVT screen/confirm ratio results that mimicked the presence of LA

Rivaroxaban plasma treated with DOAC-Stop showed correction of the clotting time Prolongation and the screen/confirm ratio for most LA tests

Participants in the study correctly identified the rivaroxaban plasma treated with DOAC-Stop as LA-negative

And exampted a corrected the prolonged clotting time induced by rivaroxaban, but displayed over-correction of the screen/confirm ratio



Approaches to Overcome Anticoagulation

- Dilution (1:1) of patient plasma into pooled normal plasma (PNP)
- Integrated assays (screen and confirm)
- Tests (reportedly) less affected by anticoagulants
- Antidotes or neutralizers to quench *in vitro* the activity of anticoagulants
- Discontinuation of anticoagulation

Discontinuation of Anticoagulation

- Oral anticoagulation may be temporarily stopped and switched to LMWH
- LMWH would protect from thrombosis, making LA detection possible
- This strategy may be considered in individual patients after full consideration of pros and cons

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic Criteria
- When testing
- Results reporting
- Interpretation

Results Reporting

LA detection should be reported with analytical results and an interpretative comment (i.e., *LA yes, or no*)

Issues on LA Detection

- Who should be tested
- Which test(s)
- Diagnostic Criteria
- When testing
- Results reporting
- Interpretation

Clinical interpretation of results

- Interpretation should consider the results of all the three tests
- The syndrome is defined if at least one of the tests (LA, aCL or aß₂GPI) is positive
- Positivity for all the three tests (triple positivity) identify patients at very high risk

LA Detection Main unresolved issues

- Standardization of existing procedures
- Application of SSC guidelines
- Urgent need for LA specific tests
- Understanding of pathogenic mechanisms may help
- Tests able to distinguish LA patients who develop clinical events from those who do not
- dRVVT better than APTT-based tests ?
- a82-GPI domain I
- Quantification of LA potency
- Establishment of "international standards" ?

Journal of Thrombosis and Haemostasis, 7: 1767–1773

DOI: 10.1111/j.1538-7836.2009.03588.x

ORIGINAL ARTICLE

The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study

B. DE LAAT, * V. PENGO, † I. PABINGER, ‡ J. MUSIAL, § A. E. VOSKUYL, ¶ I. E. M. BULTINK, ¶
A. RUFFATTI, ** B. ROZMAN, † † T. KVEDER, † † P. DE MOERLOOSE, ‡ F. BOEHLEN, § § J. RAND, ¶ ¶
Z. ULCOVA-GALLOVA, *** K. MERTENS* and P. G. DE GROOT † † †

*Department of Plasma Proteins, Sanquin Research, Amsterdam, the Netherlands; †Clinical Cardiology, Department of Cardiothoracic and Vascular Sciences, Thrombosis Centre, University of Padua, Padua, Italy; ‡Clinical Division of Haematology and Haemostaseology, Department of

Table 2 Association between aPL and thrombosis

Odds ratio (95% confidence interval)

Anti-domain I IgG	3.5 (2.3–5.4)*
Non-domain I	0.4 (0.3–0.6)
Anti-beta2GPI IgG	
Anti-beta2GPI IgM	0.9 (0.6–1.3)
LAC	1.8 (1.1-3.1)*
aCL	1.1 (0.6–2.1)


To estimate whether there is a significant increase in association of anti-domain I IgG antibodies with thrombosis an odds ratio was calculated within the total population of 511 patients. *One is not included in 95% confidence interval. Bold: Significant association of assay with clinical symptom.

Thromb Res 2915; 136: 161-63

Antibodies to Domain 4/5 (Dm4/5) of β 2-Glycoprotein 1 (β 2GP1) in different antiphospholipid (aPL) antibody profiles



V. Pengo ^{a,b,*}, A. Ruffatti ^{a,b}, M. Tonello ^{a,b}, A. Hoxha ^a, E. Bison ^a, G. Denas ^a, S. Padayattil Jose ^a, G. Zoppellaro ^a, A. Bracco ^a, A. Banzato ^a



Summary & Conclusions

- Accuracy of lab diagnosis is essential as APS patients are candidates for long term anticoagulation
- Diagnosis should be established far from acute events and off therapy
- APS requires one the following
- Positive APTT-based or dRVV tests
- aCL (aß2GPI-dependent) IgG or IgM above normal limits
- aß2GPI, IgG or IgM above normal limits
- Triple positivity identify patients at high risk